Abstract
LinusBio has raised $16 million in series A financing from investors such as GreatPoint Ventures and Bow Capital. The company will use the funds to develop and expand its exposome sequencing technology for the early detection of autism spectrum disorder and other diseases. The exposome is the collection of a person’s chemical and biological exposures over time. The goal in exposome science is to measure these exposures and map them to the individual’s health. Techniques to sequence the exposome typically involve measuring biomarkers in the blood or saliva. These samples provide a recent snapshot of a person’s surroundings. Instead, LinusBio uses human hair, which the company claims can provide a convenient readout of a person’s exposome history. The company says that a single strand of hair can provide as many as 500 timepoint measurements of the exposome. “If you were to try to reproduce what [LinusBio] does with a traditional
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
